Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 3919

Antag says it is confident ahead of 'imminent' Phase 1 obesity readout for GIP blockade

$
0
0
Antag Therapeutics is taking an unusual, although not unknown, approach to obesity. Where drugs like Eli Lilly’s Zepbound and other compounds from Roche and Viking Therapeutics have mechanisms partly based on GIP agonism, Antag is ...

Viewing all articles
Browse latest Browse all 3919